"urothelial carcinome; chromosomal abnormalities; cytology; fluorescence in situ hybridization; histology"@en . "Our Experience in Using Fluorescence in situ Hybridization FISH-Uro Vysion in Diagnostics of Uroteliel Carcinoma"@en . "1210-7875" . "Our Experience in Using Fluorescence in situ Hybridization FISH-Uro Vysion in Diagnostics of Uroteliel Carcinoma"@en . "Pac\u00EDk, Dalibor" . "V\u00EDt, V\u00EDt\u011Bzslav" . "I" . . "Votava, Milan" . . . "RIV/00216224:14110/09:00051285!RIV12-MSM-14110___" . "328532" . . "Na\u0161e zku\u0161enosti s metodou Fluorescen\u010Dn\u00ED in situ hybridizace p\u0159i detekci uroteli\u00E1ln\u00EDho karcinomu" . "Na\u0161e zku\u0161enosti s metodou Fluorescen\u010Dn\u00ED in situ hybridizace p\u0159i detekci uroteli\u00E1ln\u00EDho karcinomu" . . . "\u010Cerm\u00E1k, Ale\u0161" . . "9"^^ . . "\u0160mardov\u00E1, Jana" . "4"^^ . "Pavlovsk\u00FD, Zden\u011Bk" . "Urothelial carcinoma is a disease at high risk of recurrence after the initial therapy (70-80 %) and with the tendency to progression accomplishing the recurrence (30 %). Long lasting monitoring of patients with urothelial carcinoma is necessary. Cystoscopy and cytology are currently the primary modalities used to detect and monitor urothelial carcinoma. However, cytology has relatively poor sensitivity especially in well differentiated tumors. Cystoscopy is an invasive and relatively expensive method. Therefore, methods improving detection of urothelial carcinoma from urine specimens are employed. Uro Vysion (Vysis) fluorescence in situ hybridization (FISH) for improved detection of urothelial carcinoma was evaluated. Materials and methods: Bladder tumor progression is accompanied by increased chromosomal instability and aneuploidy of chromosomes 3, 7, 17 and loss of locus 9p21. A total of 124 patients were analyzed at Dpts. of Urology and Pathology, Faculty Hospital in Brno."@en . "Falkov\u00E1, Iva" . "uroteli\u00E1ln\u00ED karcinom (UK) je onemocn\u011Bn\u00ED s vysok\u00FDm po\u010Dtem recidiv po prvotn\u00ED l\u00E9\u010Db\u011B (70\u201380 %) a s tendenc\u00ED k progresi p\u0159i recidiv\u011B (30 %). Dlouhodob\u00E9 sledov\u00E1n\u00ED pacient\u016F s t\u00EDmto onemocn\u011Bn\u00EDm je tedy nezbytn\u00E9. Cystoskopie a cytologie jsou v sou\u010Dasnosti hlavn\u00EDmi metodami pou\u017E\u00EDvan\u00FDmi k prokazov\u00E1n\u00ED a sledov\u00E1n\u00ED uroteli\u00E1ln\u00EDch karcinom\u016F. Cytologie v\u0161ak vykazuje nedostate\u010Dnou senzitivitu, p\u0159edev\u0161\u00EDm u dob\u0159e diferencovan\u00FDch n\u00E1dor\u016F, cystoskopie pak je invazivn\u00ED a relativn\u011B drah\u00E1 metoda. Proto jsou hled\u00E1ny takov\u00E9 metody, kter\u00E9 by umo\u017Enily lep\u0161\u00ED detekci uroteli\u00E1ln\u00EDho karcinomu ze vzorku mo\u010Di. V t\u00E9to pr\u00E1ci jsou hodnoceny v\u00FDsledky pou\u017Eit\u00ED UroVysion (Vysis) fluorescen\u010Dn\u00ED in situ hybridizace (FISH) v detekci UK. Materi\u00E1l a metodika: progrese karcinomu mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e je prov\u00E1zena zv\u00FD\u0161en\u00EDm chromozom\u00E1ln\u00ED nestability a aneuploidi\u00ED chromozom\u016F 3, 7, 17 a ztr\u00E1tou lokusu 9p21. Na Urologick\u00E9 klinice a \u00DAstavu patologie FN Brno bylo vy\u0161et\u0159eno 124 pacient\u016F."@cs . . . "uroteli\u00E1ln\u00ED karcinom (UK) je onemocn\u011Bn\u00ED s vysok\u00FDm po\u010Dtem recidiv po prvotn\u00ED l\u00E9\u010Db\u011B (70\u201380 %) a s tendenc\u00ED k progresi p\u0159i recidiv\u011B (30 %). Dlouhodob\u00E9 sledov\u00E1n\u00ED pacient\u016F s t\u00EDmto onemocn\u011Bn\u00EDm je tedy nezbytn\u00E9. Cystoskopie a cytologie jsou v sou\u010Dasnosti hlavn\u00EDmi metodami pou\u017E\u00EDvan\u00FDmi k prokazov\u00E1n\u00ED a sledov\u00E1n\u00ED uroteli\u00E1ln\u00EDch karcinom\u016F. Cytologie v\u0161ak vykazuje nedostate\u010Dnou senzitivitu, p\u0159edev\u0161\u00EDm u dob\u0159e diferencovan\u00FDch n\u00E1dor\u016F, cystoskopie pak je invazivn\u00ED a relativn\u011B drah\u00E1 metoda. Proto jsou hled\u00E1ny takov\u00E9 metody, kter\u00E9 by umo\u017Enily lep\u0161\u00ED detekci uroteli\u00E1ln\u00EDho karcinomu ze vzorku mo\u010Di. V t\u00E9to pr\u00E1ci jsou hodnoceny v\u00FDsledky pou\u017Eit\u00ED UroVysion (Vysis) fluorescen\u010Dn\u00ED in situ hybridizace (FISH) v detekci UK. Materi\u00E1l a metodika: progrese karcinomu mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e je prov\u00E1zena zv\u00FD\u0161en\u00EDm chromozom\u00E1ln\u00ED nestability a aneuploidi\u00ED chromozom\u016F 3, 7, 17 a ztr\u00E1tou lokusu 9p21. Na Urologick\u00E9 klinice a \u00DAstavu patologie FN Brno bylo vy\u0161et\u0159eno 124 pacient\u016F." . "Na\u0161e zku\u0161enosti s metodou Fluorescen\u010Dn\u00ED in situ hybridizace p\u0159i detekci uroteli\u00E1ln\u00EDho karcinomu"@cs . "6"^^ . . . . "14110" . . "Svit\u00E1kov\u00E1, Milu\u0161e" . "45" . . "Na\u0161e zku\u0161enosti s metodou Fluorescen\u010Dn\u00ED in situ hybridizace p\u0159i detekci uroteli\u00E1ln\u00EDho karcinomu"@cs . . . . "RIV/00216224:14110/09:00051285" . "2" . "CZ - \u010Cesk\u00E1 republika" . . "\u010Cesko-slovensk\u00E1 patologie a soudn\u00ED l\u00E9ka\u0159stv\u00ED" . . "[0E478AE89A6B]" . "Hrab\u00E1lkov\u00E1, Renata" . .